GeoVax Labs, Inc. (NASDAQ:GOVX) Sees Significant Growth in Short Interest

GeoVax Labs, Inc. (NASDAQ:GOVX) saw a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 109,000 shares, a growth of 142.8% from the May 31st total of 44,900 shares. Based on an average trading volume of 1,060,000 shares, the short-interest ratio is presently 0.1 days. Approximately 4.4% of the shares of the stock are short sold.

GeoVax Labs Price Performance

Shares of GOVX stock traded down $0.36 on Friday, hitting $3.19. 19,815,805 shares of the company’s stock traded hands, compared to its average volume of 7,368,152. The company’s fifty day simple moving average is $1.76 and its 200 day simple moving average is $2.72. GeoVax Labs has a one year low of $1.09 and a one year high of $10.24.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($2.47) earnings per share (EPS) for the quarter. Research analysts predict that GeoVax Labs will post -7.41 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright increased their price objective on GeoVax Labs from $8.00 to $120.00 and gave the company a “buy” rating in a research report on Tuesday, June 18th.

Hedge Funds Weigh In On GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Armistice Capital LLC bought a new position in GeoVax Labs, Inc. (NASDAQ:GOVX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned about 91.38% of GeoVax Labs as of its most recent filing with the Securities & Exchange Commission. 6.09% of the stock is owned by institutional investors.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.